Overexpression of Interleukin-33 in Recombinant Rabies Virus Enhances Innate and Humoral Immune Responses through Activation of Dendritic Cell-Germinal Center Reactions.
Overexpression of Interleukin-33 in Recombinant Rabies Virus Enhances Innate and Humoral Immune Responses through Activation of Dendritic Cell-Germinal Center Reactions.
复制标题
DOI：
10.3390/vaccines10010034
复制
发表时间：
2021-12-28
期刊：
影响因子：
7.8
通讯作者：
Li Y
中科院分区：
文献类型：
--
作者：
Mi Z;Zhao L;Sun M;Gao T;Wang Y;Sui B;Li Y
狂犬病是由狂犬病病毒（RABV）引起的人畜共患传染病，病死率高达100%。全球平均每年有6万人死于狂犬病。预防和限制狂犬病的最有效方法是接种疫苗，但目前这种方法既昂贵又低效，需要3剂系列注射，每年需要接种一次。因此，研制单剂长效狂犬病疫苗迫在眉睫。本研究构建了过表达白细胞介素-33（IL-33）的重组狂犬病病毒（rRABV），命名为rLBNSE-IL-33，并在小鼠模型中评价了其作用。结果表明，rLBNSE-IL 33可以通过激活天然免疫系统的组成部分树突状细胞（DCs）来增强RABV诱导的免疫抗体的快速产生，早在免疫后3天（dpi）。此外，rLBNSE-IL 33通过调节T细胞依赖性生发中心（GC）反应诱导高水平的病毒中和抗体（VNA）产生，持续8周，从而导致更好的狂犬病保护。我们的数据表明，IL-33是一种新的佐剂，可用于通过激活DC-GC反应来增强先天性和体液免疫应答，因此，rLBNSE-IL-33可被开发为安全有效的动物疫苗。
Rabies is a zoonotic infectious disease caused by rabies virus (RABV), and its mortality rate is as high as 100%. Globally, an average of 60,000 people die from rabies each year. The most effective method to prevent and limit rabies is vaccination, but it is currently expensive and inefficient, consisting of a 3-dose series of injections and requiring to be immunized annually. Therefore, it is urgent to develop a single dose of long-acting rabies vaccine. In this study, recombinant rabies virus (rRABV) overexpressing interleukin-33 (IL-33) was constructed and designated as rLBNSE-IL33, and its effect was evaluated in a mouse model. The results showed that rLBNSE-IL33 could enhance the quick production of RABV-induced immune antibodies as early as three days post immunization (dpi) through the activation of dendritic cells (DCs), a component of the innate immune system. Furthermore, rLBNSE-IL33 induced high-level virus-neutralizing antibodies (VNA) production that persisted for 8 weeks by regulating the T cell-dependent germinal center (GC) reaction, thus resulting in better protection against rabies. Our data suggest the IL-33 is a novel adjuvant that could be used to enhance innate and humoral immune responses by activating the DC-GC reaction, and thus, rLBNSE-IL33 could be developed as a safe and effective vaccine for animals.
登录
查看更多内容
影响因子：
32.4
作者：
Flamar, Anne-Laure;Klose, Christoph S. N.;Artis, David
通讯作者：
Artis, David
DOI：
10.1084/jem.20102065
发表时间：
2011-07-04
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Lee SK;Rigby RJ;Zotos D;Tsai LM;Kawamoto S;Marshall JL;Ramiscal RR;Chan TD;Gatto D;Brink R;Yu D;Fagarasan S;Tarlinton DM;Cunningham AF;Vinuesa CG
通讯作者：
Vinuesa CG
外源IL-33恢复了既定癌症的树突状细胞的活化和成熟。
DOI：
10.4049/jimmunol.1501399
发表时间：
2017-02-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Dominguez D;Ye C;Geng Z;Chen S;Fan J;Qin L;Long A;Wang L;Zhang Z;Zhang Y;Fang D;Kuzel TM;Zhang B
通讯作者：
Zhang B
影响因子：
5.4
作者：
Haley, Shannon L.;Tzvetkov, Evgeni P.;McGettigan, James P.
通讯作者：
McGettigan, James P.
影响因子：
7.5
作者：
Luo, Ping;Deng, Shaorong;Han, Wei
通讯作者：
Han, Wei